Relay Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Relay Therapeutics, Inc.
18.35
+0.10%
vs ±17.0% implied · ×0.01
shaded = implied · ▲▼ = realized
Relay Therapeutics has 1 disclosed supplier and 2 disclosed customers in SEC filings.
Largest filed tie
—
SentenceWe paid an annual collaboration fee of up to $9.9 million to D.E. Shaw Research until the end of the initial research term.
RLAY 10-Kaccession 0001193125-26-076739
SentenceIn December 2024, we and Elevar Therapeutics, Inc., or Elevar, entered into an exclusive global licensing agreement, or the Elevar Agreement, pursuant to which Elevar was granted global development and commercialization rights for lirafugratinib.
RLAY 10-Kaccession 0001193125-26-076739
SentenceUnder the terms of the Genentech Agreement, we received $75.0 million in an upfront payment in 2021, as well as $45.0 million in milestone payments from Genentech as of December 31, 2025.
RLAY 10-Kaccession 0001193125-26-076739
Expected move
Inputsspot 18.35exp Nov 20ATM strike 18ATM straddle 2.72IV 78%